Cannabis
Conditions
Keywords
Cannabinoids, Pharmacology, Contamination, Hemp lotion
Brief summary
This study will evaluate the pharmacokinetic effects of acute and chronic dosing of a hemp-based cannabidiol (CBD) topical lotion with low levels of delta-9-tetrahydrocannabinol (THC) in a sanitized and controlled environment.
Detailed description
Participants (N = 6) will complete an 7-day residential study using a high CBD/low D9-THC lotion. The lotion is applied to the participants' upper arms four times daily in a sanitized and controlled procedure that eliminates the potential for specimen contamination. Oral fluid (OF) is collected before and after application (six samples/day); blood and urine are collected once/day. On discharge day, participants provide an intentionally contaminated OF sample. Participants return after a 7-day washout to provide 4 additional OF specimens, one "clean" and three more intentionally contaminated samples over a two-hour course.
Interventions
DRUGCBD
CBD will be topically applied
DRUGTHC
THC will be topically applied
Sponsors
Johns Hopkins University
RTI International
Substance Abuse And Mental Health Administration
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
BASIC_SCIENCE
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 55 Years
Healthy volunteers
Yes
Inclusion criteria
* Have provided written informed consent * Be between the ages of 18 and 55 * Be in good general health based on a physical examination, medical history, vital signs, and screening urine and blood tests * Test negative for recent cannabis use in urine at the screening visit and again upon admission for the inpatient stay. * Test negative for other drugs of abuse, including alcohol, at the screening visit and again upon admission for the inpatient stay. * Not be pregnant or nursing (if female). All females must have a negative serum pregnancy test at the screening visit and a negative urine pregnancy test at each study visit. * Have a body mass index (BMI) in the range of 18 to 38 kg/m2 * Blood pressure at Screening Visit does not exceed a systolic blood pressure (SBP) of 150 mmHg or a diastolic blood pressure (DBP) of 90 mmHg * Report prior experience using cannabis or CBD products.
Exclusion criteria
* Non-medical use of psychoactive drugs other than, nicotine, alcohol, or caffeine in the month prior to the screening visit. * History of or current evidence of significant medical or psychiatric illness judged by the investigator to put the participant at greater risk of experiencing an adverse event due to exposure or completion of other study procedures. * Current use of medications which, in the opinion of the investigator or medical monitor, will interfere with the study results or the safety of the subject. * History of xerostomia (dry mouth), or the presence of mucositis, gum infection or bleeding, or other significant oral cavity disease or disorder that in the investigator's opinion may affect the collection of oral fluid samples. * Known allergy to any ingredients in the study drug. * Enrolled in another clinical trial or have received any drug as part of a research study within 30 days prior to dosing.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change in concentration of oral fluid cannabinoids | Days 1-7 and Day 14 | Concentration of cannabinoids will be measured in oral fluid (unit of measurement: nanograms/mL) |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in concentration of blood cannabinoids | Days 1-7 and Day 14 | Concentration of cannabinoids will be measured in blood (unit of measurement: nanograms/mL) |
| Change concentration of urine cannabinoids | Days 1-7 and Day 14 | Concentration of cannabinoids will be measured in urine (unit of measurement: nanograms/mL) |
| Change in the number of total minutes of sleep | Days 1-7 | Change in sleep patterns. Change in the number of total minutes of sleep will be measured via vital monitoring and sleep profiling |
Countries
United States
Contacts
CONTACTLizzie Wilkerson
CONTACTTory Spindle
PRINCIPAL_INVESTIGATORTory Spindle, PhD
Johns Hopkins University
Outcome results
None listed